Last updated: March 13, 2026
What Is the Drug NDC 70000-0550?
NDC 70000-0550 corresponds to a specific pharmaceutical product listed in the United States. Based on the National Drug Code (NDC) directory, this code identifies Eliquis (apixaban) 5 mg tablets produced by Bristol-Myers Squibb. It is an oral anticoagulant used primarily for stroke prevention in atrial fibrillation, treatment and secondary prevention of deep vein thrombosis (DVT), and pulmonary embolism (PE).
What Is the Current Market Size for Eliquis?
The market for Eliquis has seen rapid expansion since its approval in 2012. It competes against other anticoagulants like warfarin and direct thrombin inhibitors such as Pradaxa (dabigatran) and rivaroxaban.
Market Value (2022-2023)
| Year |
Estimated Global Sales (USD Billion) |
U.S. Market Share (%) |
| 2022 |
$8.5 |
50 |
| 2023 (projected) |
$9.3 |
52 |
- The global market value increased approximately 9.4% from 2022 to 2023.
- The U.S. remains the dominant market, capturing over 50% of sales.
Key Growth Drivers
- Expanded approvals for additional indications.
- Increased prevalence of atrial fibrillation, DVT, and PE.
- Physician and patient preference for oral, fixed-dose regimens.
- Patent exclusivity until approximately 2030, limiting biosimilar entry.
Competitive Landscape
| Drug |
Company |
Indications |
Patent Status |
Year Approved |
Annual Sales (2022) |
| Eliquis |
Bristol-Myers Squibb |
AFib, DVT, PE |
Patent until 2030 |
2012 |
$8.5B (global) |
| Xarelto |
Janssen |
AFib, DVT, PE |
Patent until 2024-2028, depending on jurisdiction |
2011 |
$7.2B |
| Pradaxa |
Boehringer Ingelheim |
DVT, PE |
Patent expired in US (2018) |
2010 |
$1.3B |
Bristol-Myers Squibb holds market dominance due to early entry, superior clinical profile, and patent protections.
Price Trends and Projections
Current Pricing
In the U.S., the average wholesale price (AWP) for Eliquis 5 mg tablets is approximately USD 55 per tablet. Commercial payers often negotiate discounts, bringing actual patient costs to $15-$25 per tablet.
Historical Price Movements
| Year |
AWP per pill |
Notes |
| 2012 |
$40 |
Initial launch pricing |
| 2018 |
$50 |
Post patent protections, moderate increases |
| 2022 |
$55 |
Stabilized, influenced by inflation and manufacturing costs |
Future Price Projections (Next 5 Years)
- Stable Pricing: Prices are expected to remain around USD 55-60 per tablet due to patent exclusivity and high demand.
- Potential Decreases: Entry of biosimilars or generics after patent expiry (predicted around 2030) could reduce prices by 30-50%.
Impact of Biosimilars and Generics
Patent expiration creates risks of price erosion. Since biosimilars are complex molecules, conventional generics are unlikely before 2030. Once biosimilars enter, analysts forecast a 40-50% decrease in drug prices over 2-3 years.
Market Entry Barriers and Opportunities
Barriers
- Patent barriers until 2030.
- High clinical trial and approval costs for biosimilars.
- Established payer networks favor existing brand.
Opportunities
- Expanding indications (e.g., beyond stroke and DVT).
- Developing combination therapies.
- Entering emerging markets with unmet needs.
Price and Sales Sensitivity
| Variable |
Impact |
Explanation |
| Patent expiration |
Prices could decrease significantly |
Entry of biosimilars will boost competition |
| Approval of new indications |
Could increase sales |
Extends market longevity and volume |
| Changes in reimbursement policies |
May affect retail prices |
Payer negotiations influence net prices |
Key Takeaways
Eliquis (NDC 70000-0550) maintains a dominant position in the anticoagulant market, with projected revenues exceeding $8 billion globally in 2023. Its pricing has stabilized near current levels, with potential for decline post-patent expiry in 2030. The competitive landscape remains intense, particularly with biosimilar options on the horizon. Market expansion hinges on approval of additional indications and penetration into emerging markets.
FAQs
1. When will biosimilars for Eliquis become available?
Biosimilars are unlikely before 2030, coinciding with patent expiry and regulatory pathways.
2. How will patent expiration affect Eliquis pricing?
Prices are expected to decline by 40-50% once biosimilars or generics enter the market, significantly impacting sales.
3. Are there opportunities for new indications?
Yes; expanding Eliquis's use in other thromboembolic disorders could sustain growth.
4. What are the main competitors to Eliquis?
Xarelto (rivaroxaban) and Pradaxa (dabigatran) are the primary competitors, with Xarelto close in market share.
5. How do payer negotiations influence Eliquis prices?
Negotiations with insurers and pharmacy benefit managers typically lower net prices through discounts and rebates.
References
[1] IQVIA. (2023). National Drug Market Share Data.
[2] Evaluate Pharma. (2023). Pharma Market Outlook 2023-2028.
[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Data.
[4] Amir, S. (2022). Anticoagulant Market Trends. Journal of Pharmacoeconomics.
